drugset / Trial / NCT03884465

Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil

NCT03884465

NaSequentialOpen-labelTreatment

Summary

Acute and chronic hemodynamic dose-response and safety evaluation of LIQ861 in PAH subjects.

Timeline

Start
2019-11-11
Primary completion
2020-12-23
Completion
2020-12-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Treprostinil Other / unclassified 25 ug Inhaled
Subject Treprostinil Other / unclassified 50 ug Inhaled
Subject Treprostinil Other / unclassified 75 ug Inhaled
Subject Treprostinil Other / unclassified 100 ug Inhaled